Exclusivity & Patents Updated January 14, 2026

What is Patent Linkage?

Patent linkage connects patent rights to FDA regulatory approval, preventing generic approval before patent issues are resolved. Learn about the US system.

Definition

Patent Linkage is the regulatory mechanism in the US that connects patent rights to FDA approval status. Generic applicants must address all Orange Book-listed patents through certifications, and challenging patents can trigger automatic stays on approval.

How Patent Linkage Works

Brand companies list patents in the Orange Book. Generic ANDA filers must make patent certifications. Paragraph IV challenges trigger notification requirements and potential litigation stays.

The Linkage Process

  1. Brand lists patents in Orange Book at NDA approval
  2. Generic files ANDA with patent certifications
  3. Paragraph IV certification triggers 45-day lawsuit period
  4. If sued, 30-month stay blocks FDA approval
  5. Stay lifts upon court decision or 30 months, whichever first

Patent Certification Types

CertificationMeaningEffect
Paragraph INo patents listedImmediate approval possible
Paragraph IIPatents expiredImmediate approval possible
Paragraph IIIWill wait for expiryApproval after expiry
Paragraph IVInvalid/not infringedTriggers notification and potential stay

Why BD Teams Track Patent Linkage

For business development professionals, patent linkage affects generic timelines:

  • Deal Implication: Strong Orange Book patent positions delay generic entry
  • Due Diligence Focus: Evaluate patent listing strategy and Paragraph IV exposure
  • Opportunity Signal: Patent linkage dynamics create settlement and licensing opportunities

Frequently Asked Questions

What is patent linkage?

Patent linkage is the legal connection between FDA drug approval and patents, requiring generic applicants to address listed patents before approval.

How does patent linkage work in the US?

Brand companies list patents in the Orange Book; generic filers must certify regarding each patent, and certain certifications trigger automatic approval stays.

What is the 30-month stay?

When a brand company sues within 45 days of Paragraph IV notification, FDA cannot approve the ANDA for 30 months unless the case resolves sooner.

Do all countries have patent linkage?

No, patent linkage is not universal. The EU and many other countries separate patent enforcement from regulatory approval.

Can patent linkage be abused?

Critics argue that some companies list questionable patents to trigger stays, though FDA and courts have mechanisms to address improper listings.

Track Regulatory Filings with PharmaDB

Get real-time access to FDA approvals, pipeline data, and regulatory intelligence for BD teams.

Join the Waitlist